MusthInsider

Latest On DiaMedica Therapeutics Inc (DMAC):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-05-16 12:52 EST	News	DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript	N/A
2023-03-29 11:42 EST	News	DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript	N/A
2023-03-28 21:07 EST	News	DiaMedica Therapeutics GAAP EPS of -$0.52 in-line	N/A
2022-11-30 16:32 EST	News	DiaMedica: What's Happened And What's The Value Here	N/A
2022-11-09 23:13 EST	News	DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03	N/A
2022-10-27 07:45 EST	News	DiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trial	N/A
2022-08-12 01:34 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript	N/A
2022-08-11 08:38 EST	News	DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.05	N/A
2022-07-06 21:27 EST	News	FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold	N/A
2022-05-16 11:12 EST	News	DiaMedica Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation	N/A
2022-05-07 00:58 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript	N/A
2022-05-05 02:30 EST	News	DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07	N/A
2022-03-15 22:19 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call Transcript	N/A
2022-03-15 02:31 EST	News	DiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08	N/A
2022-01-05 20:09 EST	News	DiaMedica Therapeutics appoints chief medical officer	N/A
2021-11-12 00:43 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2021 Results - Earnings Call Transcript	N/A
2021-11-06 00:33 EST	News	DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.	N/A
2021-09-30 13:30 EST	News	DiaMedica gets FDA Fast Track status for acute ischemic stroke treatment DM199	N/A
2021-09-27 16:22 EST	News	DiaMedica Therapeutics to undertake $30M private equity offering	N/A
2021-09-21 16:39 EST	News	DiaMedica Therapeutics (DMAC) Investor Presentation - Slideshow	N/A
2021-08-12 15:59 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript	N/A
2021-08-11 19:36 EST	News	DiaMedica Therapeutics EPS beats by $0.05	N/A
2021-07-21 05:39 EST	News	DiaMedica: Undercovered Stroke Drug Company With Decent Data	N/A
2021-07-21 05:17 EST	News	Diamedica shows mixed results for kidney disease therapy in mid-stage study	N/A
2021-07-21 04:53 EST	News	DiaMedica Therapeutics adds two industry veterans to its board of directors	N/A
2021-05-06 10:44 EST	News	DiaMedica Therapeutics reports Q1 results	N/A
2021-03-18 12:32 EST	Analyst Rating	The Analyst Target Price has increased from $20.67 to $22.17.	Buy
2021-03-12 11:29 EST	Analyst Rating	The Analyst Target Price has increased from $19.83 to $20.67.	Buy
2021-03-12 02:43 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript	N/A
2021-03-11 15:30 EST	Financials	Company financials have been released.	Neutral
2021-03-11 11:29 EST	Earnings Estimate	An EPS average of -$1.19 is estimated for the 2022 year.	Sell
2021-03-11 11:29 EST	Earnings Estimate	An EPS average of -$0.76 is estimated for the 2021 year.	Sell
2021-03-11 11:29 EST	Earnings Estimate	An EPS average of -$0.19 is estimated for the quarter ending on June 30, 2021.	Buy
2021-03-11 06:01 EST	News	DiaMedica Therapeutics EPS misses by $0.06	N/A
2021-02-18 11:27 EST	Analyst Rating	The Analyst Target Price has increased from $16.2 to $19.83.	Buy
2021-01-05 11:39 EST	Analyst Rating	The Analyst Target Price has increased from $13.4 to $16.2.	Buy
2020-12-17 11:47 EST	Earnings Estimate	An EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021.	Buy
2020-12-17 11:47 EST	Earnings Estimate	An EPS average of -$0.16 is estimated for the quarter ending on December 31, 2020.	Buy
2020-12-17 11:47 EST	Analyst Rating	The Analyst Target Price has increased from $0 to $13.4.	Buy
2020-12-10 10:57 EST	News	DiaMedica rises 6% on successful Type B meeting with FDA for DM199 study in acute ischemic stroke	N/A
2020-11-26 19:46 EST	Financials	Company financials have been released.	Neutral
2020-11-10 19:46 EST	Financials	Company financials have been released.	Neutral
2020-11-08 07:34 EST	Financials	Company financials have been released.	Neutral
2020-11-08 05:35 EST	News	DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript	N/A
2020-11-07 15:37 EST	Financials	Company financials have been released.	Neutral
2020-11-07 11:34 EST	Financials	Company financials have been released.	Neutral
2020-11-07 07:04 EST	News	DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation	N/A
2020-11-05 03:04 EST	News	DiaMedica Therapeutics EPS misses by $0.04	N/A
2020-09-26 12:34 EST	Financials	Company financials have been released.	Neutral
2020-09-17 04:42 EST	Financials	Company financials have been released.	Neutral

About DiaMedica Therapeutics Inc (DMAC):

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

See Advanced Chart

General

Name DiaMedica Therapeutics Inc
Symbol DMAC
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 10
Last Split Factor1:20
Last Split Date2018-11-15
Fiscal Year EndDecember
IPO Date2008-01-04
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.diamedica.com

Valuation

Price/Book (Most Recent Quarter) 7.28

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$0.79
Next Year EPS Estimate -$1.30
Next Quarter EPS Estimate -$0.19
Return on Assets -43%
Return on Equity -73%
Earnings Per Share -$0.90
Revenue Per Share $0
Quarterly Earnings Growth 0%

Highlights

Market Capitalization 180.81 million
EBITDA -9387000
Analyst Target Price $22.17
Book Value Per Share $1.39

Share Statistics

Shares Outstanding 18.78 million
Shares Float 16.41 million
% Held by Insiders 672%
% Held by Institutions 39.31%
Shares Short 116640
Shares Short Prior Month 82969
Short Ratio 0.7
Short % of Float 1%
Short % of Shares Outstanding 1%

Technicals

Beta 2.43
52 Week High $10.88
52 Week Low $1.87
50 Day Moving Average 9.19
200 Day Moving Average 6.69

Dividends

Dividend Date 2018-11-15
ExDividend Date N/A
Dividend Yield 0%

DiaMedica Therapeutics Inc (DMAC) Dividend Calendar:

DMAC's last dividend payment was made to shareholders on November 15, 2018.

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

DiaMedica Therapeutics Inc (DMAC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-03-10	$N/A	-$0.23	-$0.16	-41.54%
2020-09-30	2020-11-04	$N/A	-$0.19	-$0.15	-29.52%
2020-06-30	2020-08-11	$N/A	-$0.17	-$0.14	-25.93%
2020-03-31	2020-05-13	$N/A	-$0.19	-$0.29	33.33%
2019-12-31	2020-03-23	$N/A	-$0.21	-$0.25	16%
2019-09-30	2019-11-13	$N/A	-$0.20	-$0.21	4.76%
2019-06-30	2019-08-13	$N/A	-$0.21	-$0.26	18.19%
2019-03-31	2019-05-13	$N/A	-$0.27	-$0.20	-35%
2018-12-31	2019-03-19	$-3657	-$0.11	-$0.26	57.69%
2018-09-30	2018-12-10	$503657	-$0.07
2018-06-30	2018-08-30	$N/A	-$0.46
2018-03-31	2018-04-30	$N/A	-$0.09
2017-09-30	2017-11-27	$N/A	-$0.15
2017-06-30	2017-08-29	$N/A	-$0.18
2017-03-31	2017-04-27	$N/A	-$0.24
2016-09-30	2016-11-29	$N/A	-$0.20
2016-06-30	2016-08-29	$N/A	-$0.12
2016-03-31	2016-04-29	$N/A	-$0.08
2015-09-30	2015-11-30	$N/A	-$0.07
2015-06-30	2015-08-31	$N/A	-$0.10
2015-03-31	2015-04-30	$N/A	-$0.14
2014-09-30	2014-11-28	$N/A	-$0.40	-$0.20	-100%
2014-06-30	2014-08-28	$N/A	-$0.40	-$0.60	33.33%
2014-03-31	2014-04-30	$N/A	-$0.40	-$0.40	0%
2013-09-30	2013-11-28	$N/A	-$0.47
2013-06-30	2013-08-28	$N/A	-$0.80
2013-03-31	2013-03-31	$N/A	-$1.08
2012-12-31	2012-12-31	$N/A	-$1.25
2012-09-30	2012-09-30	$N/A	-$1.02

DiaMedica Therapeutics Inc (DMAC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

DiaMedica Therapeutics Inc (DMAC) Chart:

DiaMedica Therapeutics Inc (DMAC) News:

Below you will find a list of latest news for DiaMedica Therapeutics Inc (DMAC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

DiaMedica Therapeutics Inc (DMAC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent
2025-08-15	2.5	1.9	CALL	1	20	441.81	TRUE	-0.6	-0.24
2025-08-15	5	0.27	CALL	0	497	137.15	FALSE	0	0
2025-08-15	7.5	0.24	CALL	0	10	444.46	FALSE	0	0
2025-08-15	10	0	CALL	0	0	573.45	FALSE	0	0
2025-08-15	2.5	0	PUT	0	0	292.5	FALSE	0	0
2025-08-15	5	0.5	PUT	0	149	49.67	TRUE	0	0
2025-08-15	7.5	0	PUT	0	0	240.21	TRUE	0	0
2025-08-15	10	0	PUT	0	0	301.66	TRUE	0	0
2025-09-19	2.5	1.63	CALL	0	1	284.95	TRUE	0	0
2025-09-19	5	0	CALL	0	0	83.86	FALSE	0	0
2025-09-19	7.5	0.3	CALL	0	3	122.26	FALSE	0	0
2025-09-19	10	0.34	CALL	0	4	166.6	FALSE	0	0
2025-09-19	2.5	0	PUT	0	0	256.17	FALSE	0	0
2025-09-19	5	1.14	PUT	0	1	90.71	TRUE	0	0
2025-09-19	7.5	0	PUT	0	0	87.66	TRUE	0	0
2025-09-19	10	0	PUT	0	0	127.69	TRUE	0	0
2025-10-17	2.5	2.63	CALL	0	2	182	TRUE	0	0
2025-10-17	5	0.6	CALL	0	79	76.24	FALSE	0	0
2025-10-17	7.5	0.44	CALL	0	18	98.45	FALSE	0	0
2025-10-17	10	0	CALL	0	7	128.04	FALSE	0	0
2025-10-17	12.5	0	CALL	0	0	163.23	FALSE	0	0
2025-10-17	2.5	0	PUT	0	0	153.02	FALSE	0	0
2025-10-17	5	0	PUT	0	0	58.61	TRUE	0	0
2025-10-17	7.5	0	PUT	0	0	136.21	TRUE	0	0
2025-10-17	10	6	PUT	0	12	103.69	TRUE	0	0
2025-10-17	12.5	8.4	PUT	0	6	127.87	TRUE	0	0
2026-01-16	2.5	1.6	CALL	0	77	278.65	TRUE	0	0
2026-01-16	5	1.3	CALL	0	55	70.89	FALSE	0	0
2026-01-16	7.5	0.4	CALL	0	5	84.36	FALSE	0	0
2026-01-16	10	0.65	CALL	0	2	98.96	FALSE	0	0
2026-01-16	2.5	0	PUT	0	0	81	FALSE	0	0
2026-01-16	5	1.5	PUT	0	2	54.83	TRUE	0	0
2026-01-16	7.5	0	PUT	0	0	67.99	TRUE	0	0
2026-01-16	10	0	PUT	0	0	86.26	TRUE	0	0

Latest DMAC Trades:

Date	Shares	Price
Jun 13, 2022 3:48 PM EST	100	$2.29

DiaMedica Therapeutics Inc (DMAC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Date	Form Type	Form Name	Link
2020-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm
2020-01-06	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1401040/000000000020000113/0000000000-20-000113-index.htm
2020-02-12	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1401040/000093583620000089/0000935836-20-000089-index.htm
2019-06-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000064/0001235802-19-000064-index.htm
2019-06-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000065/0001235802-19-000065-index.htm
2019-06-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000066/0001235802-19-000066-index.htm
2019-06-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000067/0001235802-19-000067-index.htm
2019-08-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm
2019-08-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm
2019-08-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm
2019-08-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm
2019-11-05	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000130/0001235802-19-000130-index.htm
2019-11-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000131/0001235802-19-000131-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000052/0001235802-20-000052-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000053/0001235802-20-000053-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000054/0001235802-20-000054-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000055/0001235802-20-000055-index.htm
2020-01-31	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1401040/000138713120000815/0001387131-20-000815-index.htm
2019-08-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774919016566/0001437749-19-016566-index.htm
2019-08-13	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774919016595/0001437749-19-016595-index.htm
2019-10-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774919020938/0001437749-19-020938-index.htm
2019-11-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774919022681/0001437749-19-022681-index.htm
2019-11-13	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774919022682/0001437749-19-022682-index.htm
2020-01-02	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1401040/000143774920000070/0001437749-20-000070-index.htm
2020-01-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920000102/0001437749-20-000102-index.htm
2020-01-07	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1401040/000143774920000296/0001437749-20-000296-index.htm
2020-02-11	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920002238/0001437749-20-002238-index.htm
2020-02-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920002240/0001437749-20-002240-index.htm
2020-02-11	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920002327/0001437749-20-002327-index.htm
2020-02-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920002598/0001437749-20-002598-index.htm
2020-03-23	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920005905/0001437749-20-005905-index.htm
2020-03-23	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920005906/0001437749-20-005906-index.htm
2020-04-20	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1401040/000143774920007997/0001437749-20-007997-index.htm
2020-04-20	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1401040/000143774920007998/0001437749-20-007998-index.htm
2020-05-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920010597/0001437749-20-010597-index.htm
2020-05-13	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920010599/0001437749-20-010599-index.htm
2020-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm
2020-08-05	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920016682/0001437749-20-016682-index.htm
2020-08-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920016685/0001437749-20-016685-index.htm
2020-08-10	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920017103/0001437749-20-017103-index.htm
2020-08-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920017105/0001437749-20-017105-index.htm
2020-08-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920017512/0001437749-20-017512-index.htm
2020-08-11	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920017514/0001437749-20-017514-index.htm
2020-11-04	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1401040/000143774920022536/0001437749-20-022536-index.htm
2020-11-04	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1401040/000143774920022537/0001437749-20-022537-index.htm
2020-01-09	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1401040/999999999520000060/9999999995-20-000060-index.htm

DiaMedica Therapeutics Inc (DMAC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of DiaMedica Therapeutics Inc (DMAC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 672%
Institutional Ownership: 3931%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2019-08-19	Scott Kellen	CFO and Secretary	Buy	3,000.00	2.43	7,290.00	10,290.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm
2020-06-01	James T. Parsons	Director	Buy	8,102.00	4.59	37,188.18	14,202.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm
2019-08-16	Dietrich John Pauls	President and CEO	Buy	1,000.00	2.68	2,676.90	30,804.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm
2019-08-16	Richard D. Pilnik	Director	Buy	7,840.00	2.56	20,039.04	50,678.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm
2020-06-01	Richard D. Pilnik	Director	Buy	10,168.00	4.59	46,671.12	60,846.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm
2019-08-16	HARRY W JR ALCORN	Chief Medical Officer	Buy	7,260.00	2.67	19,365.32	8,260.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm
2020-06-01	Randall Michael Giuffre	Director	Buy	7,784.00	4.59	35,728.56	93,588.00	https://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm

DiaMedica Therapeutics Inc

(NASDAQ:DMAC)